Poseida Therapeutics, Inc.
PSTXDelisted Jan 8, 2025- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001661460
Poseida Therapeutics, Inc. was delisted on Jan 8, 2025; its insiders filed their last Form 4 on Jan 10, 2025; 116 institutions reported holding it in 13F filings for Q4 2024, worth $519.2M in total; no superinvestor held it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 116
- Q4 2024, +20 vs. previous quarter
- 13F value
- $519.2M
- Reported value at the end of Q4 2024
- Superinvestors holding
- 0
- At the end of Q4 2024
Superinvestors holding PSTX, Q4 2024
No superinvestor reported holding PSTX at the end of Q4 2024.
Latest insider trades
Open-market purchases and sales by Poseida Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Dec 11, 2024 (view filing) | Dec 10 | 1 day | Gergen Mark JExecutive Chairman | SSale | −30.0K | $9.46 | −$283.8K | −4.4%651.3K after | 10b5-1 |
| Nov 27, 2024 (view filing) | Nov 26 | 1 day | Gergen Mark JExecutive Chairman | SSale | −30.0K | $9.27 | −$278.1K | −4.4%651.3K after | 10b5-1 |
| Aug 10, 2022 (view filing) | Aug 8 | 2 days | Ostertag EricExecutive Chairman | PPurchase | +142.9K | $3.50 | +$500.0K | +20.5%838.8K after | |
| Aug 10, 2022 (view filing) | Aug 8 | 2 days | Malin Life Sciences Holdings Ltd10% Owner | PPurchase | +2.15M | $3.50 | +$7.53M | +22.2%11.8M after | |
| Aug 5, 2022 (view filing) | Aug 3 | 2 days | Ostertag EricExecutive Chairman | SSale | −160.7K | $3.69 | −$593.0K | −100.0%0 after | |
| Mar 18, 2022 (view filing) | Mar 16 | 2 days | Ingalls Kerry D.Chief Operating Officer | PPurchase | +3.00K | $3.98 | +$11.9K | +5.8%55.0K after | |
| Dec 7, 2021 (view filing) | Dec 6 | 1 day | Malin Life Sciences Holdings Ltd10% Owner, Other: Common director with Issuer | PPurchase | +1.83K | $6.90 | +$12.6K | 0.0%9.69M after | |
| Dec 2, 2021 (view filing) | Nov 30-Dec 2 | 2 days | Malin Life Sciences Holdings Ltd10% Owner, Other: Common director with Issuer | PPurchase | +51.3K | $6.85 | +$351.2K | +0.5%9.68M after | 3 lots |
| Nov 29, 2021 (view filing) | Nov 24-29 | 5 days | Malin Life Sciences Holdings Ltd10% Owner, Other: Common director with Issuer | PPurchase | +39.4K | $6.83 | +$269.0K | +0.4%9.63M after | 3 lots |
| Nov 23, 2021 (view filing) | Nov 19-23 | 4 days | Malin Life Sciences Holdings Ltd10% Owner, Other: Common director with Issuer | PPurchase | +25.7K | $7.06 | +$181.6K | +0.3%9.59M after | 2 lots |
Top 10 13F holders, Q4 2024
The largest institutional positions in Poseida Therapeutics, Inc. at the end of Q4 2024; share changes are against Q3 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| FMR LLC | 10,011,617 | $96.1M | 0.01% | −4,558,461−31.3% | Reduced |
| Pentwater Capital Management LP | 8,625,000 | $82.8M | 1.43% | +2,650,000+44.4% | Added |
| BlackRock, Inc. | 5,631,488 | $54.1M | 0.00% | +507,519+9.9% | Added |
| Nomura Holdings Inc | 5,115,015 | $49.1M | 0.26% | +5,115,015 | New |
| Vanguard Group Inc | 3,834,519 | $36.8M | 0.00% | +171,063+4.7% | Added |
| Alpine Associates Management Inc. | 2,016,700 | $19.4M | 1.18% | +2,016,700 | New |
| Boxer Capital Management, LLC | 2,000,000 | $19.2M | 1.63% | +2,000,000 | New |
| Geode Capital Management, LLC | 1,629,759 | $15.6M | 0.00% | +12,622+0.8% | Added |
| State Street Corp | 1,594,542 | $15.3M | 0.00% | −116,023−6.8% | Reduced |
| Aisling Capital Management LP | 1,043,267 | $10.0M | 3.55% | 00.0% | Unchanged |